Summary
The bulk drug industry is a global industry. The products produced in one region are consumed in some other region-distinguished only by quality and cost. Some pharmaceutical companies are combining producers in developed markets and their counterparts in India and China into a complex supply chain becoming more responsive and cost-effective. The global bulk drugs market, worth an estimated US$77.33 billion in 2005, grew at a compounded annual growth rate (CAGR) of 9.2% in the last five years. The branded prescription drugs accounted for nearly 86% of the bulk drug consumption in 2005. Of late, the generic prescription drugs segment has emerged as a promising market for bulk drugs. The bulk drug industry is highly-fragmented, with a large number of small players. The bulk drug producers can be classified into three categories: Contract manufacturers, Niche bulk drug manufacturers and Commodity bulk drug manufacturers. The contract manufacturing of over-the-counter and nutritional products is the largest and fastest growing segment., The report includes executive summary, highlights, market overview of global pharma and bulk drugs, growth drivers, issues and challenges, regulatory issues, major players, critical success factors and future outlook. The report also provides the sub- category wise analysis, Top 10 bulk drugs in the world, the high potency bulk drugs market, regional opportunities in API's, cGMP's in USA, Europe, Japan & India, drug master files & drug regulation in China and mergers & acquisitions etc., SCOPE OF THE REPORT - , The report takes the global bulk drug market in perspective and then the various sub segments. It gives the market overview of Global Pharma and then global bulk drugs. It focuses on the following points - , The category wise analysis - its growth drivers, key issues and future outlook, Top 10 bulk drugs in the world, The high potency bulk drugs market, The regional opportunities in API's, The growth drivers and issues & challenges, The major players (Profiles of 15 major players in the world. Each profile covers business and financial profile, key strategies and outlook.), The regulatory issues - cGMP's in USA, Europe, Japan & India, Drug master files & Drug regulation in China, The impact of mergers & acquisitions among fine chemicals companies, Critical success factors, The vertical integration between generic companies and the research based pharmaceutical companies and, Future outlook, FOR WHOM - , Bulk Drug companies, Contract manufacturing companies, Pharmaceutical companies, Consultants, Industry & Trade Associations, No of Pages : 98, List of Tables : 9, List of Charts : 8
|
